
### üß† Neurology: Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Management

#### ‚úÖ True Statements
1. **Anterior ischemic optic neuropathy (AION)** presents with **acute, painless, monocular vision loss** accompanied by **blurred optic disc margins** and a **pale or swollen optic disc** on funduscopic examination.
2. **Anterior ischemic optic neuropathy (AION)** occurs in **arteritic** and **nonarteritic** forms.
3. **Arteritic AION** is most commonly associated with **giant cell arteritis (GCA)** and frequently includes **headache**, **jaw claudication**, and **elevated inflammatory markers**.
4. **Nonarteritic AION** is strongly associated with **small‚Äëvessel disease risk factors**, especially **hypertension**, and additional systemic symptoms usually **do not** accompany the vision loss.
5. **Nonarteritic AION** is **typically not an emergency**.
6. **No effective treatment** exists to **reverse visual impairment** in **nonarteritic AION**.
7. **Nonarteritic AION** is **managed** by **controlling blood pressure** and **cardiovascular risk factors**.
8. **Dual antiplatelet therapy** (for example, **aspirin plus clopidogrel**) has **not** been shown to **improve outcomes** in **nonarteritic AION**.
9. **Carotid atherosclerosis** is **unlikely** to cause **AION**; carotid disease more commonly causes **amaurosis fugax** (transient monocular visual loss) rather than sustained vision loss with funduscopic changes.
10. **High‚Äëdose glucocorticoids** should be **initiated before temporal artery biopsy** when **giant cell arteritis (GCA)** is **strongly suspected**.
11. **Cardioembolic sources** very **rarely** cause **AION**; **transthoracic echocardiography** is **unnecessary** in the **absence of cardiac symptoms**.
12. **Risk‚Äëfactor control**, including **hypertension** and **cigarette smoking**, may **reduce recurrence** of **AION**.

#### üí¨ Extra
10. Inflammatory markers commonly used when assessing **giant cell arteritis (GCA)** include **erythrocyte sedimentation rate (ESR)** and **C‚Äëreactive protein (CRP)**.

#### üè∑Ô∏è Tags
#Neurology #AmbulatoryCare #NeuroOphthalmology #IschemicOpticNeuropathy #NAION #GiantCellArteritis

#### üìö Reference
Biousse V, Newman NJ. Ischemic optic neuropathies. *N Engl J Med*. 2015;372:2428-36. PMID: 26083207 doi:10.1056/NEJMra1413352

#### üÜî Question ID
NRMCQ24077

#### üïí Last Updated
February 2025

---

#### üìñ Related Text
MKSAP¬†19: Neurology ‚Äî Neuro‚Äëophthalmology, Optic Neuropathies, Optic Neuropathies

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. **Giant cell arteritis (GCA)** is an **ophthalmologic emergency** and should be **excluded in adults aged ‚â•50 years** who present with **transient or permanent monocular vision loss**, **regardless of pain**.
2. **High‚Äëdose glucocorticoids** may **limit vision loss** in **giant cell arteritis (GCA)** and should be started **urgently**.
3. In **optic neuritis**, **intravenous methylprednisolone** **shortens recovery time** and **reduces 2‚Äëyear incidences** of **recurrence** or **conversion to multiple sclerosis (MS)**.
4. **Glucocorticoids are not recommended** in **nonarteritic anterior ischemic optic neuropathy (NAION)** or in **central/branch retinal artery occlusion** **unless giant cell arteritis is suspected**.
5. **Retinal artery occlusion** can originate from **carotid artery stenosis** or **cardioembolic sources**.
6. **Thrombolysis** can be used for **retinal artery occlusion** if the patient **presents within 4.5 hours** (noting **off‚Äëlabel use after 3 hours**).
7. **Optic neuritis** typically presents with **vision loss over hours to days** and **eye pain worsened by eye movement**.
8. The funduscopic appearance in **optic neuritis** may include **papillitis**; in younger patients, a **pale, flat optic disc (optic nerve atrophy)** may be observed.
9. **Optic neuritis** may be **idiopathic** or represent the **initial manifestation** of **multiple sclerosis (MS)** or **neuromyelitis optica spectrum disorder (NMOSD)**.
10. **Vision** in **optic neuritis** may **improve over weeks to months without treatment**, and **intravenous methylprednisolone** **hastens improvement**.
11. **Arteritic AION** presents with **acute transient or permanent vision loss** and a **pale, swollen optic disc with blurred margins** and **retinal pallor** on examination.
12. Evaluation of **arteritic AION** includes **erythrocyte sedimentation rate (ESR)**, **C‚Äëreactive protein (CRP)**, and **temporal artery biopsy**.
13. **Urgent methylprednisolone** followed by **prednisone** is recommended for **arteritic AION**.
14. **Nonarteritic AION** usually reflects **microvascular disease**; **embolic sources** or **carotid stenosis** are **uncommon**, and **investigations for these are not required** in typical cases.
15. **Central or branch retinal artery occlusion** presents with **acute painless vision loss** and a **well‚Äëdemarcated optic disc** with a **pale retina**.
16. Evaluation of **central or branch retinal artery occlusion** should **urgently** include **carotid duplex ultrasonography**, **magnetic resonance angiography (MRA)** or **computed tomographic angiography (CTA)**, and **echocardiography** to assess for **cardioembolic sources**.
17. **Papilledema** is caused by **increased intracranial pressure** and may produce **brief (seconds‚Äëlong) visual symptoms** that are common but **not typically the presenting symptom**.
18. Funduscopic examination in **papilledema** shows **optic disc swelling with blurred margins**; **hemorrhages** and **cotton‚Äëwool spots** may be seen in the **acute phase**.
19. **Papilledema** requires **urgent neuroimaging** with **brain MRI (preferred)** or **head CT** to **exclude intracranial mass**; if imaging is **normal**, **lumbar puncture** should be performed to **measure opening pressure**.
20. **Management of papilledema** is **directed at the cause** of the **elevated intracranial pressure**.
21. The **differential diagnosis of optic neuropathy** includes **optic neuritis**, **ischemic optic neuropathy** (anterior or posterior), **infiltrative**, **compressive**, **toxic**, **hereditary**, **nutritional‚Äëdeficiency**, and **traumatic** optic neuropathies.
22. **Infiltrative optic neuropathy** causes include **optic glioma**, **sarcoidosis**, **lymphoma**, **leukemia**, and **metastatic carcinoma**.
23. **Compressive optic neuropathy** causes include **local or metastatic malignancy**, **orbital pseudotumor**, **thyroid ophthalmopathy**, and **papilledema** due to **increased intracranial pressure**.
24. **Toxic optic neuropathy** causes include **ethylene glycol**, **amiodarone**, and **ethambutol**.
25. **Hereditary optic neuropathy** causes include **Leber hereditary optic neuropathy (LHON)** and **dominant optic atrophy**.
26. **Nutritional deficiency‚Äìrelated optic neuropathy** can be caused by **vitamin B12 deficiency**.
27. **Ischemic optic neuropathy** can be **anterior (AION)** or **posterior (PION)** and may also occur after **radiation** exposure.

#### üí¨ Extra
6. The time‚Äëwindow statement reflects common practice patterns noted in teaching tables: **thrombolysis** for **retinal artery occlusion** is considered **within 4.5 hours** of onset, with **off‚Äëlabel use after 3 hours**.
14. Statements 14‚Äì16 reflect summarized rows from the **‚ÄúClinical Presentation, Diagnosis, and Treatment of Selected Monocular Optic Neuropathies‚Äù** table; exact wording is normalized for stand‚Äëalone clarity.
21. Statement 21 consolidates categories from the **‚ÄúCauses of Optic Neuropathy‚Äù** table to serve as a differential diagnosis anchor.

#### üè∑Ô∏è Tags
#NeuroOphthalmology #OpticNeuritis #GiantCellArteritis #RetinalArteryOcclusion #Papilledema #CarotidStenosis

---

#### üóæ Supplemental Tables
<table>
  <caption><strong>Causes of Optic Neuropathy</strong></caption>
  <thead>
    <tr>
      <th>Category</th>
      <th>Conditions or Other Causes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Optic neuritis</td>
      <td>Idiopathic; multiple sclerosis; neuromyelitis optica spectrum disorder</td>
    </tr>
    <tr>
      <td>Ischemic optic neuropathy</td>
      <td>Anterior ischemic optic neuropathy (AION) and posterior ischemic optic neuropathy (PION); radiation</td>
    </tr>
    <tr>
      <td>Infiltrative optic neuropathy</td>
      <td>Optic glioma; sarcoidosis; lymphoma; leukemia; metastatic carcinoma</td>
    </tr>
    <tr>
      <td>Compressive optic neuropathy</td>
      <td>Local or metastatic malignancy; orbital pseudotumor; thyroid ophthalmopathy; papilledema (increased intracranial pressure)</td>
    </tr>
    <tr>
      <td>Toxic optic neuropathy</td>
      <td>Ethylene glycol; amiodarone; ethambutol</td>
    </tr>
    <tr>
      <td>Hereditary optic neuropathy</td>
      <td>Leber hereditary optic neuropathy (LHON); dominant optic atrophy</td>
    </tr>
    <tr>
      <td>Nutritional deficiency</td>
      <td>Vitamin B<sub>12</sub> deficiency</td>
    </tr>
    <tr>
      <td>Traumatic optic neuropathy</td>
      <td>‚Äî</td>
    </tr>
  </tbody>
</table>
<p><em>AION = anterior ischemic optic neuropathy; LHON = Leber hereditary optic neuropathy; PION = posterior ischemic optic neuropathy.</em></p>

<table>
  <caption><strong>Clinical Presentation, Diagnosis, and Treatment of Selected Monocular Optic Neuropathies</strong></caption>
  <thead>
    <tr>
      <th>Category</th>
      <th>Presentation</th>
      <th>Funduscopic Appearance</th>
      <th>Potential Cause / Necessary Evaluation</th>
      <th>Treatment</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Optic neuritis</td>
      <td>Vision loss over hours to days; eye pain that worsens with eye movement</td>
      <td>Papillitis; pale, flat optic disc (optic nerve atrophy) in younger patients</td>
      <td>Idiopathic or initial manifestation of multiple sclerosis or neuromyelitis optica spectrum disorder</td>
      <td>Vision may improve over weeks to months without treatment; intravenous methylprednisolone hastens improvement</td>
    </tr>
    <tr>
      <td>Arteritic AION</td>
      <td>Acute transient or permanent vision loss</td>
      <td>Pale and swollen optic disc; blurred margins; pale retina</td>
      <td>Giant cell arteritis; obtain ESR and CRP; temporal artery biopsy</td>
      <td>Urgent methylprednisolone followed by prednisone</td>
    </tr>
    <tr>
      <td>Nonarteritic AION</td>
      <td>Acute painless vision loss; may progress over days to weeks</td>
      <td>Same as directly above (pale and swollen disc with blurred margins; retinal pallor)</td>
      <td>Microvascular disease; embolic source or carotid artery stenosis is uncommon; investigations for these are usually not needed</td>
      <td>No effective treatment to reverse impairment; glucocorticoids not recommended unless giant cell arteritis is suspected</td>
    </tr>
    <tr>
      <td>Central or branch retinal artery occlusion</td>
      <td>Acute painless vision loss</td>
      <td>Well-demarcated optic disc; pale retina</td>
      <td>Carotid artery stenosis and cardiac embolism; urgent carotid duplex ultrasonography, MRA, or CTA; urgent echocardiography to rule out cardioembolic source</td>
      <td>Secondary prevention of vascular events; thrombolysis if presenting within 4.5 hours (off-label after 3 hours)</td>
    </tr>
    <tr>
      <td>Papilledema</td>
      <td>Brief (usually seconds) visual symptoms common but not the presenting symptom</td>
      <td>Optic disc swelling with blurred margins; hemorrhages and cotton-wool spots may be seen in the acute phase</td>
      <td>Caused by increased intracranial pressure; urgent brain MRI (preferred) or head CT to rule out intracranial mass; lumbar puncture to measure opening pressure if brain imaging is normal</td>
      <td>Management based on condition responsible for elevated intracranial pressure</td>
    </tr>
  </tbody>
</table>
<p><em>AION = anterior ischemic optic neuropathy; CRP = C-reactive protein; CTA = CT angiography; ESR = erythrocyte sedimentation rate; MRA = magnetic resonance angiography.</em></p>
<p><em><sup>a</sup> See Figure: Fundus Image Showing Optic Nerve Papillitis.<br>
<sup>b</sup> See Figure: Fundus Image Showing Optic Disc Pallor.<br>
<sup>c</sup> See Table: Differential Diagnosis of Multiple Sclerosis and Table: Inflammatory Causes of Noncompressive Myelopathy.<br>
<sup>d</sup> See Figure: Fundus Image Showing Anterior Ischemic Optic Neuropathy.<br>
<sup>e</sup> See Figure: Fundus Image Showing Branch Retinal Artery Occlusion.<br>
<sup>f</sup> See Secondary Prevention of Ischemic Stroke in Neurology.<br>
<sup>g</sup> See Figure: Fundus Image Showing Papilledema.</em></p>

### üñºÔ∏è Supplemental Figure

<figure>
  <img src="Fundus%20Image%20Showing%20Anterior%20Ischemic%20Optic%20Neuropathy.jpg" alt="Fundus photograph: arteritic anterior ischemic optic neuropathy with swollen, pale optic disc and blurred margins compared with a normal optic disc." />
  <figcaption><strong>Fundus Image Showing Anterior Ischemic Optic Neuropathy.</strong> The left image, of anterior ischemic optic neuropathy secondary to giant cell arteritis, shows a swollen, pale optic disc (thicker arrow); blurred margins (thin arrow); and a pale retina. The right image shows a normal optic disc (arrow).</figcaption>
</figure>
